{"entity":{"id":"nct07545603","kind":"trial","name":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","aka":[],"tldr":"A phase 2 trial of XNW5004 in follicular lymphoma, run by Evopoint Biosciences Inc., now recruiting.","summary":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT07545603 by Evopoint Biosciences Inc., with 65 participants planned, started 2026-02-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: XNW5004 tablets. Conditions listed: Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3, Follicular Lymphoma Grade 3A. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07545603","url":"https://clinicaltrials.gov/study/NCT07545603"}],"tags":["ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["xnw5004"],"companies":["evopoint-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07545603","phase":"2","setting":"Phase II Study of XNW5004 in the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma (EZH2 Wild-type)","sponsor":"Evopoint Biosciences Inc.","enrolled":65,"outcomes":[]},"route":"/trials/nct07545603/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"drug":[{"id":"xnw5004","kind":"drug","name":"XNW5004","route":"/drugs/xnw5004/"}],"company":[{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/"}]}}